https://orcid.org/0000-0001-8006-4861
References
- Kim LA, D’Amore PA. A brief history of anti-VEGF for the treatment of ocular angiogenesis. Am J Pathol. 2012;181(2):376–379. doi:https://doi.org/10.1016/j.ajpath.2012.06.006.
- Ramulu PY, Do DV, Corcoran KJ, Corcoran SL. Robin Al: use of retinal procedures in Medicare beneficiaries from 1997 to 2007. Arch Ophthalmol. 2010;128:1335–1340. doi:https://doi.org/10.1001/archophthalmol.2010.224.
- Klein KS, Walsh MK, Hassan TS, et al. Endophthalmitis after anti-VEGF injections. Ophthalmology. 2009;116:1225. doi:https://doi.org/10.1016/j.ophtha.2009.02.031.
- Day S, Acquah K, Mruthyunjaya P, et al. Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration. Am J Ophthalmol. 2011;152:266–272. doi:https://doi.org/10.1016/j.ajo.2011.01.053.
- Moshfeghi AA, Rosenfeld PJ, Flynn HW, et al. Endophthalmitis after intravitreal anti–vascular endothelial growth factor antagonists. Retina. 2011;31:662–668. doi:https://doi.org/10.1097/IAE.0b013e31821067c4.
- Gregori NZ, Flynn HW Jr, Schwartz SG, et al. Current infectious endophthalmitis rates after intravitreal injections of antivascular endothelial growth factor agents and outcomes of treatment. Ophthalmic Surg Lasers Imaging Retina. 2015;46:643–664. doi:https://doi.org/10.3928/23258160-20150610-08.
- Rayess N, Rahimy E, Storey P, et al. Postinjection endophthalmitis rates and characteristics following intravitreal bevacizumab, ranibizumab, and aflibercept. Am J Ophthalmol. 2016;165:88–93. doi:https://doi.org/10.1016/j.ajo.2016.02.028.
- VanderBeek BL, Bonaffini SG, Ma L. Association of compounded bevacizumab with post injection endophthalmitis. JAMA Ophthalmol. 2015;133:1159–1164. doi:https://doi.org/10.1001/jamaophthalmol.2015.2556.
- Shanmugam PM. Changing paradigms of anti-VEGF in the Indian scenario. Indian J Ophthalmol. 2014;62(1):88–92. doi:https://doi.org/10.4103/0301-4738.126189.
- Das T, Volety S, Ahsan S, et al. Safety, sterility and stability of direct-from-vial multiple dosing intravitreal injection of bevacizumab. Clin Exp Ophthalmol. 2015;43(5):466–473. doi:https://doi.org/10.1111/ceo.12489.
- Raman R, Singh HS, Appanraj R, et al. Five-Year Incidence and Visual Outcomes in Post Intravitreal Injection Endophthalmitis. Ophthalmology. 2016;123(5):1162–1164. doi:https://doi.org/10.1016/j.ophtha.2015.11.019.
- Beri S, Shandil A, Garg R. Stenotrophomonas maltophilia: an emerging entity for cluster endophthalmitis. Indian J Ophthalmol. 2017;65(11):1166. doi:https://doi.org/10.4103/ijo.IJO_314_17.
- Agarwal A, Aggarwal K, Samanta R, et al. Cluster endophthalmitis due to Stenotrophomonas maltophilia following intravitreal bevacizumab: outcomes of patients from North India. British J Ophthalmol. 2018;103(9):1278–1283. doi:https://doi.org/10.1136/bjophthalmol-2018-313131.
- Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Endophthalmitis vitrectomy study group. Arch Ophthalmol. 1995;113:1479‐1496.
- Standardization of Uveitis Nomenclature for Reporting Clinical Data. Results of the first international workshop. Am J Ophthalmol. 2005;140(3):509–516. doi:https://doi.org/10.1016/j.ajo.2005.03.057.
- Nussenblatt RB, Whitcup SM. Uveitis: Fundamentals and Clinical Practice. 3rd. Philadelphia: Mosby; 2004.
- Garcia-Aguirre G, Vanzinni-Zago V, Quiroz-Mercado H. Growth of Scytalidium sp. in a counterfeit bevacizumab bottle. Indian J Ophthalmol. 2013;61(9):523. doi:https://doi.org/10.4103/0301-4738.119455.
- Hoevenaars N, Gans D, Missotten T, van Rooij J, Lesaffre E, van Meurs J. Suspected bacterial endophthalmitis following intravitreal anti-VEGF injection: case series and literature review. Ophthalmologica. 2012;228(3):143–147. doi:https://doi.org/10.1159/000339584.
- Sridhar J, Flynn H, Kuriyan A, Dubovy S, Miller D. Endophthalmitis caused by klebsiella species. Retina. 2014;34(9):1875–1881. doi:https://doi.org/10.1097/IAE.0000000000000162.
- Yang C, Tsai H, Sung C, Lin K, Lee F, Hsu W. Endogenous Klebsiella endophthalmitis associated with pyogenic liver abscess. Ophthalmology. 2007;114(5):876–880. doi:https://doi.org/10.1016/j.ophtha.2006.12.035.
- Lee Y, Sohn SJ, Lee S. Result of early vitrectomy for endogenous klebsiella pneumoniae endophthalmitis. Retina. 2003;23(3):366–370. doi:https://doi.org/10.1097/00006982-200306000-00013.
- Chaudhary K, Romero J, Ezon I, Fastenberg D, Deramo V. Pars plana vitrectomy in the management of patients diagnosed with endophthalmitis following intravitreal anti-vascular endothelial growth factor injection. Retina. 2013;33(7):1407–1416. doi:https://doi.org/10.1097/IAE.0b013e3182807659.
- Rayess N, Obeid A, Storey P, et al. Long-term visual outcomes and clinical features after anti–vascular endothelial growth factor injection–related endophthalmitis. Retina. 2019;39(11):2070–2076. doi:https://doi.org/10.1097/IAE.0000000000002300.
- Haripriya A, Chang D, Namburar S, Smita A, Ravindran R. Efficacy of intracameral moxifloxacin endophthalmitis prophylaxis at aravind eye hospital. Ophthalmology. 2016;123(2):302–308. doi:https://doi.org/10.1016/j.ophtha.2015.09.037.